| Federico Milla, MD | |
|
95 Collier Rd Nw, Suite 5015, Atlanta, GA 30309-1796 | |
| (404) 605-2800 | |
| (404) 351-5983 |
| Full Name | Federico Milla |
|---|---|
| Gender | Male |
| Speciality | Thoracic Surgery |
| Experience | 24 Years |
| Location | 95 Collier Rd Nw, Atlanta, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346393238 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208G00000X | Thoracic Surgery (cardiothoracic Vascular Surgery) | 069356 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Joseph Hospital | Denver, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Scl Health Medical Group - Denver Llc | 0840513552 | 414 |
News Archive
The moment we open our eyes, we perceive the world with apparent ease. But the question of how neurons in the retina encode what we "see" has been a tricky one. A key obstacle to understanding how our brain functions is that its components-neurons-respond in highly nonlinear ways to complex stimuli, making stimulus-response relationships extremely difficult to discern.
A meeting with the US regulatory agency FDA held on July 17 has confirmed that the Swedish pharmaceutical company Orexo is on track with its preparation for a regulatory submission of a new drug approval (NDA) for its medicine for treatment of opioid dependency, OX219.
China Medical Technologies, Inc., a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that the Company has received approval for its SPR- based analysis system (the "SPR System") from the State Food and Drug Administration of China (the "SFDA").
In a new study led by UCLA Jonsson Comprehensive Cancer Center member Dr. Roger Lo, researchers have uncovered how melanoma becomes resistant to a promising new drug combo therapy utilizing BRAF+MEK inhibitors in patients after an initial period of tumor shrinkage.
Allakos Inc. announced today that it has completed a $32 million Series A preferred stock financing led by Novo Ventures with participation from Alta Partners, RiverVest Venture Partners and the Roche Venture Fund. Peter Moldt , PhD., Partner at Novo Ventures, Robert Alexander , PhD., Director at Alta Partners and John McKearn PhD., Managing Director at RiverVest Venture Partners, will join the Board of Directors.
› Verified 1 days ago
| Entity Name | Scl Health Medical Group - Denver Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083021083 PECOS PAC ID: 0840513552 Enrollment ID: O20150106000131 |
News Archive
The moment we open our eyes, we perceive the world with apparent ease. But the question of how neurons in the retina encode what we "see" has been a tricky one. A key obstacle to understanding how our brain functions is that its components-neurons-respond in highly nonlinear ways to complex stimuli, making stimulus-response relationships extremely difficult to discern.
A meeting with the US regulatory agency FDA held on July 17 has confirmed that the Swedish pharmaceutical company Orexo is on track with its preparation for a regulatory submission of a new drug approval (NDA) for its medicine for treatment of opioid dependency, OX219.
China Medical Technologies, Inc., a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that the Company has received approval for its SPR- based analysis system (the "SPR System") from the State Food and Drug Administration of China (the "SFDA").
In a new study led by UCLA Jonsson Comprehensive Cancer Center member Dr. Roger Lo, researchers have uncovered how melanoma becomes resistant to a promising new drug combo therapy utilizing BRAF+MEK inhibitors in patients after an initial period of tumor shrinkage.
Allakos Inc. announced today that it has completed a $32 million Series A preferred stock financing led by Novo Ventures with participation from Alta Partners, RiverVest Venture Partners and the Roche Venture Fund. Peter Moldt , PhD., Partner at Novo Ventures, Robert Alexander , PhD., Director at Alta Partners and John McKearn PhD., Managing Director at RiverVest Venture Partners, will join the Board of Directors.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Federico Milla, MD 95 Collier Rd Nw, Suite 5015, Atlanta, GA 30309-1796 Ph: (404) 605-2800 | Federico Milla, MD 95 Collier Rd Nw, Suite 5015, Atlanta, GA 30309-1796 Ph: (404) 605-2800 |
News Archive
The moment we open our eyes, we perceive the world with apparent ease. But the question of how neurons in the retina encode what we "see" has been a tricky one. A key obstacle to understanding how our brain functions is that its components-neurons-respond in highly nonlinear ways to complex stimuli, making stimulus-response relationships extremely difficult to discern.
A meeting with the US regulatory agency FDA held on July 17 has confirmed that the Swedish pharmaceutical company Orexo is on track with its preparation for a regulatory submission of a new drug approval (NDA) for its medicine for treatment of opioid dependency, OX219.
China Medical Technologies, Inc., a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that the Company has received approval for its SPR- based analysis system (the "SPR System") from the State Food and Drug Administration of China (the "SFDA").
In a new study led by UCLA Jonsson Comprehensive Cancer Center member Dr. Roger Lo, researchers have uncovered how melanoma becomes resistant to a promising new drug combo therapy utilizing BRAF+MEK inhibitors in patients after an initial period of tumor shrinkage.
Allakos Inc. announced today that it has completed a $32 million Series A preferred stock financing led by Novo Ventures with participation from Alta Partners, RiverVest Venture Partners and the Roche Venture Fund. Peter Moldt , PhD., Partner at Novo Ventures, Robert Alexander , PhD., Director at Alta Partners and John McKearn PhD., Managing Director at RiverVest Venture Partners, will join the Board of Directors.
› Verified 1 days ago
Peter Walter Barrett, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 95 Collier Road, Nw, Suite 5015, Atlanta, GA 30309 Phone: 404-605-5699 Fax: 404-355-4235 | |
Dr. Louis G Prevosti, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 1100 Johnson Ferry Rd Ne, Suite 165, Atlanta, GA 30342 Phone: 404-446-2800 Fax: 404-446-2809 | |
Dr. John David Vega, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 1365 Clifton Rd Ne, Suite A2200, Atlanta, GA 30322 Phone: 404-778-5040 Fax: 404-778-4346 | |
Paul Jubeong Chai, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Medicare Enrolled Practice Location: 1405 Clifton Rd Ne, Atlanta, GA 30322 Phone: 404-785-6330 Fax: 404-785-6266 | |
Dr. Eric Louis Sceusi, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 95 Collier Rd Nw, Suite 2055, Atlanta, GA 30309 Phone: 404-605-5699 | |
Dr. Robert A Guyton, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 1365 Clifton Rd Ne, Suite A2200, Atlanta, GA 30322 Phone: 404-778-5040 Fax: 404-778-4346 | |
Dr. Tarek Mohamed Kandeel, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Not Enrolled in Medicare Practice Location: 1365a Clifton Rd Ne, Cardiothoracic Surgery Department, Atlanta, GA 30322 Phone: 404-287-4346 |